<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01032668</url>
  </required_header>
  <id_info>
    <org_study_id>BYİEAH2</org_study_id>
    <nct_id>NCT01032668</nct_id>
  </id_info>
  <brief_title>The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance</brief_title>
  <acronym>EFFICIENT</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Bursa Postgraduate Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bursa Postgraduate Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Continuing high dose clopidogrel treatment after elective PCI decreased adverse cardiac&#xD;
      events in patients with clopidogrel resistance&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim:&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
        -  To evaluate the effect of continuing high dose clopidogrel treatment on adverse cardiac&#xD;
           events after elective PCI in patients with clopidogrel resistance&#xD;
&#xD;
      Secondary objective:&#xD;
&#xD;
        -  To evaluate the effect of continuing high dose clopidogrel treatment on adverse cardiac&#xD;
           events after elective PCI&#xD;
&#xD;
        -  To evaluate the effect of continuing high dose clopidogrel treatment on bleeding&#xD;
           complications after elective PCI&#xD;
&#xD;
        -  To evaluate the clinical effect of VerifyNow which use as a clopidogrel resistance kit.&#xD;
&#xD;
      Study central:&#xD;
&#xD;
      Bursa Postgraduate Hospital, Cardiology Clinic&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      we planned to enrol 180 patients. 50% of patients without clopidogrel resistance (control&#xD;
      group: 90 patients) 50% have clopidogrel resistance. Than we randomise the patients (with&#xD;
      clopidogrel resistance) in two groups (group 1:45 patients (75mg/day), group 2:45 patients&#xD;
      (150mg/day))&#xD;
&#xD;
      inclusion criteria:&#xD;
&#xD;
        -  The patients; who have planned elective PCI and have had written informed consent for&#xD;
           participation to study.&#xD;
&#xD;
        -  Age&gt;18 year-old,&#xD;
&#xD;
        -  The native coronary artery;lesion with narrowing &gt;=70%&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  Patients have allergy for ASA, Clopidogrel and heparin&#xD;
&#xD;
        -  Patients who performed primary PCI&#xD;
&#xD;
        -  Patients with acute coronary syndrome&#xD;
&#xD;
        -  Patients with have a history of PCI and use clopidogrel&#xD;
&#xD;
        -  Patients on warfarin therapy&#xD;
&#xD;
        -  Patients who have bleeding diathesis, or have high risk for bleeding.&#xD;
&#xD;
      Study works:&#xD;
&#xD;
        -  Write case report form for all patients&#xD;
&#xD;
        -  Control for inclusion criteria.&#xD;
&#xD;
        -  Evaluate the clopidogrel and ASA resistance with VerifyNow kit. Than randomised the&#xD;
           patients.&#xD;
&#xD;
        -  Demographic data (age, gender)&#xD;
&#xD;
        -  Height, weight, BMI and GFR&#xD;
&#xD;
        -  Risk factors&#xD;
&#xD;
        -  laboratory data (biochemical and hematologic)&#xD;
&#xD;
        -  Medication history&#xD;
&#xD;
        -  Echocardiographic data&#xD;
&#xD;
        -  Angiographic data&#xD;
&#xD;
        -  PCI data(vessel diameter, stent diameter, lesion and stent length, performed PTCA or&#xD;
           not, etc)&#xD;
&#xD;
        -  Note complication (MACE, bleeding, hematoma etc)&#xD;
&#xD;
           4 weeks later note the first control data and re assess the clopidogrel resistance with&#xD;
           VerifyNow kit in patients groups 1 and 2.&#xD;
&#xD;
      Six months later note the second control data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death, MI, TVR revascularization, stroke (MACCE) within 30 days and 6 moths</measure>
    <time_frame>6 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major or minor bleeding according to TIMI criteria 30 days and 6 months To evaluate the clinical effect of VerifyNow which use as a clopidogrel resistance kit 30 days and 6 months.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">192</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>high dose clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>high dose clopidogrel continuing after percutaneous coronary intervention</description>
    <arm_group_label>high dose clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patients; who have planned elective PCI and have had written informed consent for&#xD;
             participation to study.&#xD;
&#xD;
          -  Age&gt;18 year-old,&#xD;
&#xD;
          -  The native coronary artery;lesion with narrowing &gt;=70%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients have allergy for ASA, Clopidogrel and heparin&#xD;
&#xD;
          -  Patients who performed primary PCI&#xD;
&#xD;
          -  Patients with acute coronary syndrome&#xD;
&#xD;
          -  Patients with have a history of PCI and use clopidogrel&#xD;
&#xD;
          -  Patients on warfarin therapy&#xD;
&#xD;
          -  Patients who have bleeding diathesis, or have high risk for bleeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hasan ARI, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bursa Postgraduate Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi</name>
      <address>
        <city>Bursa</city>
        <zip>16320</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Aleil B, Jacquemin L, De Poli F, Zaehringer M, Collet JP, Montalescot G, Cazenave JP, Dickele MC, Monassier JP, Gachet C. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv. 2008 Dec;1(6):631-8. doi: 10.1016/j.jcin.2008.09.004.</citation>
    <PMID>19463377</PMID>
  </reference>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>December 14, 2009</study_first_submitted>
  <study_first_submitted_qc>December 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2009</study_first_posted>
  <last_update_submitted>December 14, 2009</last_update_submitted>
  <last_update_submitted_qc>December 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi</name_title>
    <organization>Cardiology</organization>
  </responsible_party>
  <keyword>percutaneous coronary intervention, clopidogrel resistance, ASA resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

